Screener / SEC EDGAR /CIK 0001356576 /10-K filed Mar 2, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care · Pharmaceuticals

Supernus, Inc. SUPN

Compare with peers Embed
The 10-K against last year's

219 changes: 64 added, 66 removed, 84 reworded, 5 quiet changes

10-K Mar 2, 2026 vs Feb 25, 2025

10-K 0001356576-26-000011 (Mar 2, 2026) vs 10-K 0001356576-25-000017 (Feb 25, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

406 paragraphs · 34 new · 86 reworded · 46 gone · 10-K Mar 2, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 111 · 48% changed Every version of it
We rely on third-party collaborators and strategic partners to market and commercialize our products and product candidates outside the U.S. We are party to and rely on several arrangements with third parties which provide us with rights to intellectual property that are necessary for the development of certain of our product candidates. In addition, we may enter into similar arrangements in the future for other product candidates. Our current arrangements impose various development, financial and other obligations on us. If we materially breach these obligations, of if third parties fail to adequately perform their respective obligations, these arrangements could be terminated which could result in our inability to develop, manufacture, market and sell products that are covered by such intellectual properties. We may not have sufficient resources to successfully establish future collaborations or license future arrangements on acceptable terms, if at all. We also face competition in our search have agreements with leading CMOs to manufacture other commercial products and the API for collaborators and licensing partners. By entering into strategic collaborations or similar arrangements, we rely on third parties to financially support their local operations, including support required for development, commercialization, sales, marketing, and regulatory activities, as well as expertise in each of those subject areas. such products
Paragraph 92 · 42% changed Every version of it
In addition to competition for our current commercial products, we anticipate that we will face intense competition when if our pipeline product candidates are approved by regulatory authorities and begin their commercialization process. In particular, we are aware of Serina Therapeutics developing a product candidate that may compete with ONAPGO (formerly SPN-830). Also, AbbVie has developed and received FDA approval in October 2024 to market a subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson disease (PD).
Paragraph 42 · 36% changed Every version of it
As evidenced by the passage of the American Rescue Plan Act of 2021 and Inflation Reduction Act of 2022, discussed in greater detail below, and the President's Executive Orders in 2025, we expect these challenges to continue and to potentially intensify during 2025, 2026, as political pressures mount, and healthcare payors, including government-controlled health authorities, insurance companies, and managed care organizations, step up initiatives to reduce the overall cost of healthcare, restrict access to higher-priced new medicines, increase the use of generic products and impose overall price cuts. Such pressures could have a material adverse impact on our business, financial condition, and results of operations.
Paragraph 333 · 35% changed Every version of it
Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations. New income, sales and use or other tax laws or regulations could be enacted or promulgated at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws and regulations could be interpreted, modified or applied adversely to us. These events could require us to pay additional taxes on a prospective or retroactive basis, as well as penalties, interest and other costs for past amounts deemed to be due. New laws or regulations, or laws or regulations that are changed, modified or newly interpreted or applied, also could create new or increase our existing compliance, operating and other costs, as well as the costs of our products. Further, the Reconciliation Act of 2017 enacted many significant changes to the U.S. tax laws, some of which were further modified in recent years, among others, by the Coronavirus Aid, Relief, and Economic Security Act, Act of 2020, the Inflation Reduction Act of 2022 and more significantly by the Reconciliation Act of 2025, all of which may be further modified in the future by the current or a future presidential administration. Among other changes, the Tax Reconciliation Act of 2017 amended the Internal Revenue Code of 1986, as amended (Code), to require that certain research and experimental expenditures be capitalized and amortized over five years if incurred in the United States or fifteen years if incurred in foreign jurisdictions for tax years beginning after December 31, 2021. Although the U.S. Congress has considered legislation that would defer, modify, or repeal The Reconciliation Act of 2025, however, permanently repealed the capitalization and amortization requirement, there requirement for domestic research and experimental expenditures paid or incurred in tax years beginning after December 31, 2024, provides an option for taxpayers to capitalize and amortize such expenditures over at least 60 months, and offers transition rules permitting the deduction of unamortized domestic research and experimental expenditures paid or incurred in tax years 2022 through 2024. No changes were made by the Reconciliation Act of 2025 with respect to the capitalization and amortization requirement for research and experimental expenditures incurred in foreign jurisdictions. If and to the extent the immediate expensing for domestic research and experimental expenditures is no assurance that such changes will be made. If repealed or any of the requirement is not deferred, repealed capitalization and amortization requirements reenacted or otherwise modified, it may increase our cash taxes and effective tax rate. In addition, it is uncertain if and to what extent various states will conform to current federal law, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net operating losses, and other deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of our deferred tax assets and could increase our future tax expense.
Paragraph 388 · 35% changed Every version of it
We may not be able to make improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. In addition, we rely on various information technology, and systems, some of which are dependent on services provided by third parties, to manage our technology platform and operations. These systems provide critical data and services for internal and external users, including procurement, inventory management, transaction processing, financial, commercial, and operational data, human resources management, legal and tax compliance, financial reporting, and other information necessary to operate and manage our business. These systems are complex and are frequently updated as technology improves. This includes software and hardware that is licensed, leased, or purchased from third parties. If our information technology, equipment, or systems fail to function properly due to internal errors or defects, implementation or integration issues, catastrophic events, cyberattacks, telecommunications delays or failures or power outages, we may experience a material disruption in our ability to manage our business operations. Failure or disruption of these systems could have an adverse effect on our operating results and financial condition. In addition, we may not be able to make improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Any failure to manage, expand, or update our information technology infrastructure, or any failure in the operation of this infrastructure, could harm our business.
Paragraph 24 · 33% changed Every version of it
Third parties have, and in the future may, receive approval to manufacture and market their own versions of products containing one or more of the active pharmaceutical ingredients present in our products in the U.S. For example, Upsher-Smith launched Qudexy XR (extended-release topiramate) and a branded generic version of Qudexy XR in 2014. Upsher-Smith also entered into a settlement with two generic companies to launch a generic to Qudexy XR in 2020. In February 2021, one of the generic companies, Glenmark, entered the U.S. market with its own therapeutically equivalent generic products to Qudexy XR.
Paragraph 200 · 33% changed Every version of it
In addition, the Company could receive adverse publicity as a result of any such failure to comply with HealthCare Reform Law. Certain provisions of the HealthCare Reform Law have not been fully interpreted by the regulatory authorities or the courts and certain provisions are subject to a variety of interpretations, which may complicate the Company's compliance with the HealthCare Laws. Any action against the Company for violation of the HealthCare Laws, even if successfully defended, could cause the Company to incur significant legal expenses and divert management's attention from the operation of its business.
Paragraph 54 · 32% changed Every version of it
We are dependent on obtaining regulatory approval of our product candidates and approval for additional indications for existing products. Our business depends on successful clinical development i.e., successful completion of clinical trials and completion of requisite manufacturing information. We are not permitted to market any of our a product candidates candidate in the U.S. until we receive approval of an NDA from the FDA or market in any foreign jurisdiction until we receive approval from the requisite authority. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity, and novelty of the product, and requires the expenditure of substantial resources. We cannot predict whether or when we will obtain regulatory

MD&A

107 paragraphs · 30 new · 52 reworded · 20 gone · 10-K Mar 2, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 68 · 50% changed
Amortization of intangible decreased assets increased from $82.4 million in 2023 to $78.0 million in 2024. 2024 to $89.5 million in 2025. The decrease increase is primarily due to impairment charges on certain acquired ONAPGO and ZURZUVAE intangible assets in the fourth quarter of 2023 which reduced amortization expense in fiscal year 2024, as well as on 2025 offset by amortization expense in 2024 for Oxtellar XR, XR and Namzaric intangible assets, which was were fully amortized in 2024. Prior to the FDA approval of ONAPGO in February 2024, ONAPGO was previously accounted for as an indefinite-lived intangible asset not subject to amortization. ZURZUVAE intangible asset was acquired as part of September 2024 and therefore, no further amortization expense was recognized the Sage Acquisition in the fourth quarter of 2024. July 2025.
Paragraph 70 · 45% changed
Contingent consideration was a gain loss of $25.4 million for the years year ended December 31, 2024 2025, and December 31, 2023 a gain of $6.1 million and $1.5 million, for the year ended December 31, 2024, respectively. The change of $4.6 million was primarily driven by the non achievement due to an increase in fair value of the 2024 sales-based milestone Sage contingent consideration associated with the Adamas Acquisition. regulatory and commercial milestone with the approval of ZURZUVAE for the treatment of MDD in Japan in December 2025, and the accretion of the USWM contingent consideration liabilities to the full milestone payment amounts with the approval of ONAPGO by the FDA in February 2025.
Paragraph 33 · 44% changed
experience. The Company has entered into settlement and license agreements with third parties, permitting the sale of a generic version of Trokendi XR beginning in January 2023. In addition, the Company entered into settlement and license agreements with third parties, permitting the sale of a generic version of Oxtellar XR beginning in September 2024. The Company is actively monitoring returns activity in light of the loss of exclusivity and actual and possible further future sales decline based on timing of generic entry. The entry of a generic competitor may cause our future Trokendi XR and Oxtellar XR product return rates to change from historical trends, and this change could have a material effect on the future provision for product returns. Historically, we have experienced changes in estimates in return reserve calculations, but those adjustments have not been material to net earnings. earnings (loss). Adjustments related to prior year sales for product returns in 2025 and 2024 was less than 4% of net product sales for each respective period and was less than 1% of net product sales in 2023. However, given the extensive number of inputs and assumptions, described above, future changes in our return reserves could be material.
Paragraph 96 · 44% changed
In this section, we discuss Further, with the results Sage Acquisition in the third quarter of 2025, our operations for investment balance decreased as marketable securities were sold to fund the year ended December 31, 2024, compared acquisition of Sage. Refer to the year ended December 31, 2023. Our Annual Report on Form 10-K for the year ended December 31, 2023, includes a discussion and analysis of our financial condition and results of operations for the year ended December 31, 2022, in Part II, Item 7—Management's 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations. Operations and Management's discussion on Financial Condition, Liquidity and Capital Resources of this Annual Report on Form 10-K for the period ended December 31, 2025, and Note 1, Business Organization, in the Notes to the Consolidated Financial Statements in Part II, Item 8 of this Annual Report.
Paragraph 72 · 44% changed
Other income (expense) was an income of Interest and other income, net decreased to $13.3 million in 2025 from $16.2 million in 2024 compared to an income of $8.0 million in 2023. 2024. The increase decrease was due to higher lower interest income on marketable securities largely driven by an overall higher investment balance sale of marketable securities holdings of which the proceeds were used to partially fund the Sage Acquisition in 2024 and no debt outstanding in 2024. The interest expense recognized in 2023 was related to the 2023 Notes which were paid off in April 2023. July 2025.
Paragraph 74 · 44% changed
Income tax expense (benefit) was $24.0 a benefit of $10.5 million and $1.5 expense of $24.0 million for the years ended December 31, 2024 2025 and December 31, 2023, 2024, respectively. The 2024 2025 income tax expense benefit is primarily driven by an increase in pre-tax book income loss as compared to prior year. The effective tax rate is impacted by benefits from the favorable effect of state taxes and the research and development credits and capital losses that were mostly credit, which is offset by an increase in the deferred effect of expenses related to current and prior year transactions that are not deductible for tax asset valuation allowance purposes. Included within transaction costs are payments to former employees of Sage which are not deductible for net operating losses and investments during the year. The 2023 income tax expense and effective tax rate was primarily driven by near break even pre-tax book income. purposes.
Paragraph 93 · 43% changed
As of December 31, 2025, no amounts are due from the contingent consideration milestone payable related to the Adamas Acquisition. As of December 31, 2024, there was one remaining outstanding milestone, Milestone 2025. Milestone 2025 (subject to certain terms and conditions and may only be achieved once) is payable upon the first occurrence of the achievement of aggregate worldwide net sales of GOCOVRI in excess of $225 million during any consecutive twelve-month period ending on or before December 31, 2025. At December 31, 2025, Milestone 2025 (Milestone 2025) was not met in 2025 and may only be achieved once. therefore is no longer outstanding nor payable.
Paragraph 63 · 42% changed
R&D expenses increased decreased from $91.6 million in 2023 to $108.8 million in 2024. 2024 to $106.2 million in 2025. The increase decrease was primarily due to increased decreased clinical program costs on SPN-817, SPN-820, partially offset by the open-label study increase in clinical program costs on SPN-817 and the Company's share of Qelbree, and increased manufacturing costs R&D expenses from the collaboration arrangement with Biogen. The Company acquired a collaboration agreement with Biogen as part of our product candidates. the acquisition of Sage in July 2025.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Legal Proceedings341 words changed in this paragraph; it is 53% similar to last year's version.
The Company received a Paragraph IV Notice Letter from generic drug maker Ascent Pharmaceuticals makers Aurobindo Pharma Limited and Aurobindo Pharma U.S.A., Inc. (collectively, Aurobindo) dated June 15, 2023, May 29, 2025, directed to ten six of its Trokendi XR® Qelbree® Orange Book patents. Supernus’s U.S. Patent Nos. 8,298,576; 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; 9,358,204; 9,603,853; 9,662,338; 11,324,753; 11,458,143; and 10,314,790 12,121,523 generally cover once-a-day topiramate viloxazine formulations and methods of treating or preventing seizures and migraines using those formulations. The FDA Orange Book currently lists United States Patent Nos. 9,358,204 and 9,603,853 as expiring on February 7, 2033; United States Patent No. 8,298,576 9,662,338 as expiring on April 4, 2028, 2, 2035; and United States Patent Nos. 8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989; 9,549,940; 9,555,004; 9,622,983; 11,324,753; 11,458,143; and 10,314,790 12,121,523 as expiring on November 16, 2027. September 4, 2029. On July June 26, 2023, 2025, the Company filed a lawsuit against Ascent Pharmaceuticals Inc., ("Ascent Pharma") Camber Pharmaceuticals, Inc., and Hetero Labs Ltd. (collectively, “Ascent”) Aurobindo alleging infringement of the Company’s Trokendi XR® Qelbree® Orange Book patents. The Complaint—filed in the U.S. District Court for the District of New Jersey—alleges, among other things, inter alia, that Ascent Aurobindo infringed the Company’s Trokendi XR® Qelbree® patents by submitting to the FDA an Abbreviated New Drug Application (“ANDA”) (ANDA) seeking to market a generic version of Trokendi XR® Qelbree® prior to the expiration of the Company’s patents. Filing its July June 26, 2023 2025, Complaint within 45 days of receiving Ascent’s Aurobindo’s Paragraph IV certification notice entitles Supernus to an automatic stay preventing the FDA from approving Ascent’s Aurobindo’s ANDA for 30 months from the date of the Company’s receipt of the Paragraph IV Notice Letter. until October 2, 2028. On September 28, 2023, the Court entered a stipulation of dismissal without prejudice as to only defendants Camber and Hetero, which included stipulations that, among other things: (i) Ascent Pharma will not contest personal jurisdiction or venue in this District for this Action; (ii) Camber and Hetero will be bound by any injunction in this Action to the extent it concerns the Ascent ANDA; and (iii) Ascent Pharma will collect and produce any relevant discovery that is in the possession, custody, or control of Camber and Hetero. On October 11, 2023, Ascent Pharma August 29, 2025, Aurobindo answered the Complaint and denied the substantive allegations of the Complaint, asserting affirmative defenses that include non-infringement and invalidity. On December 23, 2025, the Court issued an order consolidating this lawsuit for all pretrial purposes with the lawsuits against (i) Appco and Somerset, discussed in Section IV, above; (ii) Apotex, discussed in Section VIII, below; (iii) Zydus, discussed in Section IX, below; (iv) Creekwood, discussed in Section X, below; (v) MSN, discussed in Section XII, below; (vi) Zenara and Biophore, discussed in Section XIV, below; and (vii) Macleods, discussed in Sections XV and XVII, below. The Company entered into a settlement agreement with Ascent Pharma, Court’s December 23, 2025, consolidation order recaptioned the consolidated lawsuits as In re Viloxazine, C.A. No. 25-cv-12183 (MEF)(MAH) (Consolidated), and on May 2, 2024, a stipulation of dismissal without prejudice was entered by administratively terminated the U.S. District Court for the District of New Jersey. The agreement has been submitted to the applicable governmental agencies. C.A. No. 25-cv-12186 (MEF)(MAH) (D.N.J.) action.

Source: Item 3, 10-K 0001356576-26-000011 vs Item 3, 10-K 0001356576-25-000017

Risk Factors341 words changed in this paragraph; it is 50% similar to last year's version.
Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations. New income, sales and use or other tax laws or regulations could be enacted or promulgated at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws and regulations could be interpreted, modified or applied adversely to us. These events could require us to pay additional taxes on a prospective or retroactive basis, as well as penalties, interest and other costs for past amounts deemed to be due. New laws or regulations, or laws or regulations that are changed, modified or newly interpreted or applied, also could create new or increase our existing compliance, operating and other costs, as well as the costs of our products. Further, the Reconciliation Act of 2017 enacted many significant changes to the U.S. tax laws, some of which were further modified in recent years, among others, by the Coronavirus Aid, Relief, and Economic Security Act, Act of 2020, the Inflation Reduction Act of 2022 and more significantly by the Reconciliation Act of 2025, all of which may be further modified in the future by the current or a future presidential administration. Among other changes, the Tax Reconciliation Act of 2017 amended the Internal Revenue Code of 1986, as amended (Code), to require that certain research and experimental expenditures be capitalized and amortized over five years if incurred in the United States or fifteen years if incurred in foreign jurisdictions for tax years beginning after December 31, 2021. Although the U.S. Congress has considered legislation that would defer, modify, or repeal The Reconciliation Act of 2025, however, permanently repealed the capitalization and amortization requirement, there requirement for domestic research and experimental expenditures paid or incurred in tax years beginning after December 31, 2024, provides an option for taxpayers to capitalize and amortize such expenditures over at least 60 months, and offers transition rules permitting the deduction of unamortized domestic research and experimental expenditures paid or incurred in tax years 2022 through 2024. No changes were made by the Reconciliation Act of 2025 with respect to the capitalization and amortization requirement for research and experimental expenditures incurred in foreign jurisdictions. If and to the extent the immediate expensing for domestic research and experimental expenditures is no assurance that such changes will be made. If repealed or any of the requirement is not deferred, repealed capitalization and amortization requirements reenacted or otherwise modified, it may increase our cash taxes and effective tax rate. In addition, it is uncertain if and to what extent various states will conform to current federal law, or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net operating losses, and other deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses could have a material impact on the value of our deferred tax assets and could increase our future tax expense.

Source: Item 1A, 10-K 0001356576-26-000011 vs Item 1A, 10-K 0001356576-25-000017

MD&A168 words changed in this paragraph; it is 69% similar to last year's version.
We maintain a return policy that allows our customers to return products within a specified period of time. Sales of our products are not subject to a general right of return; however, we will accept return of expired product 6 months prior to, and up to 12 twelve months subsequent to, the product's expiry date for certain products. Our products have a shelf life of up to 48 months from date of manufacture. The product return accrual is estimated principally based on historical experience, the level and estimated shelf life of inventory in the distribution channel, changes in the current wholesaler prices, our return policy and expected market events, including generic competition. The time lag from date of sale of our products when we accrue our provision for product returns and the time at which we issue credit for expired product can occur up to several years after the sale of our product. Estimates associated with our provision for product returns are particularly susceptible to adjustment given the extensive time lag. The Company launched Qelbree in May 2021. The Company is actively monitoring returns activity in light of the timeline from the date of sale and the time at which we issue credit for expired products. We had favorable actual returns in 2024 and 2025 for Qelbree and as a result, the Company changed its estimated provision for Qelbree product returns based on the most recent experience. The Company has entered into settlement and license agreements with third parties, permitting the sale of a generic version of Trokendi XR beginning in January 2023. In addition, the Company entered into settlement and license agreements with third parties, permitting the sale of a generic version of Oxtellar XR beginning in September 2024. The Company is actively monitoring returns activity in light of the loss of exclusivity and actual and possible further future sales decline based on timing of generic entry. The entry of a generic competitor may cause our future Trokendi XR and Oxtellar XR product return rates to change from historical trends, and this change could have a material effect on the future provision for product returns.

Source: Item 7, 10-K 0001356576-26-000011 vs Item 7, 10-K 0001356576-25-000017

Accounting Policies136 words changed in this paragraph; it is 43% similar to last year's version.
ASU 2023-09, 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40) - Targeted Improvements to Income Tax Disclosures the Accounting for Internal-Use Software (Topic 740) 350) - The new standard, issued in December 2023, September 2025, modernizes the accounting for internal-use software. ASU 2025-06 removes all references to software development stages and requires entities to disclose additional information with respect capitalization of software costs when management has committed to the effective tax rate reconciliation software project and to disclose it is probable the disaggregation by jurisdiction of income tax expense software will be completed and income taxes paid. The standard is effective with annual periods beginning after December 15, 2024, with early adoption permitted. The standard is to be applied on a prospective basis, although optional retrospective application is permitted. perform its intended use. The Company plans to adopt the guidance for the fiscal year ending December 31, 2025. We expect ASU 2023-09 to require additional disclosures in the notes to our consolidated financial statements. 2028. The Company is currently evaluating the method of its adoption of ASU 2025-06, and the effects the adoption of this guidance will have on the consolidated financial statements.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001356576-26-000011 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001356576-25-000017

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of SUPN's Risk Factors and MD&A, 10-K Mar 2, 2026 against 10-K Feb 25, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Third parties have developed, received FDA approval and successfully commercialized longer-lasting extended relief levodopa/carbidopa products, which are impacting sales of APOKYN because they reduce the number of times per day a given patient may need to use an off-episode product like APOKYN.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedRisk Factors
Third parties have also developed, received FDA approval and successfully commercialized products that compete with ONAPGO. For example, in 2024, AbbVie launched Vyalev, a treatment for advanced PD that utilizes a wearable pump to provide a continuous infusion of foscarbidopa and foslevodopa.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedRisk Factors
We have post-marketing commitments for ZURZUVAE including the requirement to (i) conduct an embryofetal development study in a second species and (ii) Pediatric Research Equity Act sNDA as an efficacy supplement, including proposed labeling updates, and also plans to include nonclinical labeling and carton/container artwork updates.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedRisk Factors
The commercial results of ZURZUVAE® (zuranolone) depend, in part, on our ability, with our collaboration partner, Biogen MA Inc., and Biogen International GmbH, or together, Biogen, to successfully continue the commercialization of the product for the treatment of women with postpartum depression, or PPD, in the U.S. There is no assurance that our commercialization efforts in the U.S. with respect to ZURZUVAE for the treatment of women with PPD will be successful or that we will be able to generate revenues at the levels or on the timing we expect or at levels or on the timing necessary to support our goals.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedRisk Factors
The commercial results of ZURZUVAE depend, in part, on our ability, along with our collaboration partner, Biogen, to successfully continue the commercialize of ZURZUVAE in the U.S. for the treatment of women with PPD. ZURZUVAE was approved by the United States Food and Drug Administration, or FDA, in August 2023 as a treatment for adults with PPD and became commercially available in the U.S. in December 2023.
Read it in 10-K Mar 2, 2026 at sec.gov
Show the other 69
AddedRisk Factors
ZURZUVAE is the first oral treatment specifically indicated for adults with PPD. ZURZUVAE may not achieve, or, even if achieved, maintain, broad market acceptance. Healthcare professionals may decide not to use ZURZUVAE as a treatment option for their patients with PPD or may only consider prescribing ZURZUVAE for a subset of women with PPD in their practice who they consider to have particularly severe symptoms relative to other patients suffering from this disease. ZURZUVAE also may not achieve or, even if achieved, maintain broad market acceptance among women with PPD who may decide that they do not want to be treated with ZURZUVAE, including due to concern about the safety and tolerability profile of ZURZUVAE or use of ZURZUVAE while breastfeeding. ZURZUVAE includes a boxed warning that instructs healthcare professionals to advise patients that ZURZUVAE causes driving impairment due to central nervous system depressant effects, and that people who take ZURZUVAE should not drive a motor vehicle or engage in other potentially hazardous activities requiring complete mental alertness until at least 12 hours after ZURZUVAE administration for the duration of the once-daily, 14-day treatment course, which could decrease willingness to prescribe or use ZURZUVAE. The label also includes information about adverse events and other warnings and precautions that may cause a woman with PPD not to consider ZURZUVAE as a treatment option.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedRisk Factors
ZURZUVAE also may not achieve or, even if achieved, maintain broad market acceptance for the treatment of women with PPD if payors are not willing to cover and provide reimbursement for the treatment or impose significant restrictions on reimbursement. Payors that currently have favorable coverage for ZURZUVAE for the treatment of women with PPD may decide to change their policies and limit coverage or reimbursement for ZURZUVAE, including by requiring women with PPD to try other treatments prior to ZURZUVAE, requiring a specific showing of symptom severity with the use of measurement scales, requiring prior consultation with a psychiatrist or other specialist, or imposing other onerous prior authorization requirements, or they may deny coverage or reimbursement for other reasons or in all cases. Some payors currently require that healthcare professionals attest that the women with PPD for whom they have prescribed ZURZUVAE have severe symptoms. In addition, even if a healthcare professional writes a prescription for ZURZUVAE for the treatment of a woman with PPD, the prescription may not result in product being shipped to the patient and/or the patient taking ZURZUVAE. The healthcare professional or the patient may, for example, not take the steps necessary to obtain reimbursement or to have the prescription filled at the specialty pharmacy or may find the process of obtaining a prescription through the specialty pharmacy too slow or complicated. There is no guarantee that the infrastructure, systems, processes, policies, relationships or materials we and Biogen have built for the commercialization of ZURZUVAE for the treatment of women with PPD in the U.S. will be sufficient for us to achieve or, even if achieved, maintain success.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedRisk Factors
Our commercialization of ZURZUVAE in PPD may be negatively impacted by competition from other drugs currently on the market or that may be approved in the future. The number of women with PPD, the unmet need for additional treatment options for women with PPD, and the potential market for ZURZUVAE may be significantly smaller than we expect, or we and Biogen may encounter other market-related issues in the commercialization of ZURZUVAE for the treatment of women with PPD, including as a result of the price we charge. We and our collaboration partner, Biogen, may not be applying the optimal resources to the launch of ZURZUVAE or we or Biogen may not be able or willing to scale our resources at the right time or at an effective level.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedRisk Factors
During 2025 several Executive Orders were issued by the President of the United States, which generally aim to lower the price paid for certain pharmaceutical products in the United States. Aspects of these orders direct the Secretary of Health and Human Services to develop implementation plans and to issue related regulations.
Read it in 10-K Mar 2, 2026 at sec.gov
RemovedRisk Factors
the "Business" section of this report, sales of a generic version of Trokendi XR® and Oxteller XR® began in January 2023 and September 2024, respectively. Those competitive products have significantly impacted the sales of Trokendi XR and Oxtellar XR, resulting in an adverse impact on our revenue and profit. In addition, our revenue and profit could be significantly impacted by the timing and rate of commercial acceptance of key new products.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
In February 2025, the FDA approved ONAPGO (apomorphine hydrochloride) injection (formerly SPN-830), as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. See Item 1. Business for further information.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
working toward meeting these post-marketing commitments for Qelbree in a timely manner. We also have post-marketing commitment to conduct a new leachable study for ONAPGO, which was approved by the FDA in February 2025.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
We also have agreements with leading CMOs to manufacture other commercial products and the API for such products. These CMOs offer a comprehensive range of contract manufacturing services.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
We have a license agreement with United Therapeutics Corporation to use one of our proprietary technologies in an oral formulation of treprostinil diethanolamine, or treprostinil, for the treatment of pulmonary arterial hypertension and for other indications. The Company is eligible to receive, and has received royalties under this agreement based on net product sales of United Therapeutics Corporation's product, Orenitram (treprostinil). We are entitled to receive milestones and royalties for the use of this formulation in indications other than arterial hypertension.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type is currently marketed by Allergan plc under an exclusive license agreement between Adamas Pharmaceuticals, LLC and Forest Laboratories Holdings Limited ("Forest"), an indirect, wholly-owned subsidiary of Allergan plc (collectively, "Allergan") in the United States. Adamas Pharmaceuticals LLC receives royalties on net sales of Namzaric.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
In February 2025, the FDA approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
In March 2010, a comprehensive change to the U.S. healthcare system, known as the Patient Protection and Affordable Care Act of 2010 (ACA) was enacted, as amended by the Health Care and Education Reconciliation Act of 2010. These laws and their regulations (collectively "HealthCare Reform Law") have far reaching consequences for pharmaceutical companies like the Company. Possible revisions to the HealthCare Reform Law are the subject of continuing legislative debates and litigation.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
The HealthCare Reform Law exerts downward pressure on pharmaceutical pricing, especially under the Medicare and Medicaid programs, and has increased the industry's regulatory burden and operating costs. Among the provisions of the HealthCare Reform Law of importance to the Company's products and product candidates are the following:
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
•An annual, nondeductible fee payable to the U.S. federal government by any entity that manufactures or imports specified branded prescription drugs or biologic agents. This fee is based on each company's market share of prior year total sales of branded products to certain federal healthcare programs;
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
•Rebates owed by manufacturers under the Medicaid Drug Rebate Program (MDRP) for drugs that are inhaled, infused, instilled, implanted, or injected. During 2020, the Centers for Medicare & Medicaid Services (CMS) issued a Final Rule that makes significant modifications to the Medicaid Drug Rebate Program regulations in several areas, including with respect to the treatment of value-based purchasing arrangements, the definition of key terms, and the price reporting treatment of manufacturer-sponsored patient benefit programs. On May 26, 2023, CMS issued a proposed rule seeking to implement policies in the MDRP related to the new legislative requirements in the Medicaid Services Investment and Accountability Act of 2019 to address, among other things, drug misclassification and drug pricing and product data misreporting by manufacturers
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedRisk Factors
Security breaches and other disruptions could compromise our information and expose us to liability which would cause our business and reputation to suffer. 53 • Compliance with the terms and conditions of our Corporate Integrity Agreement requires significant resources and management time and, if we fail to comply, we could be subject to penalties or, under certain circumstances, excluded from government healthcare programs, which would materially adversely affect our business. 56 Risks Related to Our Finances and Capital Requirements • Tariffs may increase our costs. 62 • Our operating results may fluctuate significantly. 56 62 • Our ability to use our net operating loss carryforwards and other tax attributes may be limited or may expire prior to utilization. 57 63 • We have and may further expand our business through acquisitions of new product lines or businesses, which expose us to various risks, including difficulties in integrating acquisitions.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
If we fail to comply with our obligations under any of these arrangements, we could lose the benefit of such collaborative relationships, including licenses or intellectual property rights. 39 45 • Our failure to successfully develop and market our product candidates would impair our ability to grow. 40 47 • Our clinical trials for our product candidates may fail to demonstrate acceptable levels of safety, efficacy, or other requirements, which could prevent or significantly delay regulatory approval. 41 48 • Delays or failures in the completion of clinical development of our product candidates would increase our costs, delay, or limit our ability to generate revenues. 42 48 • Healthcare reform measures could hinder or prevent the commercial success of our products or product candidates. 44 50 • Healthcare cost containment legislation and the failure of third-party payors to provide appropriate levels of coverage and reimbursement for the use of products and treatments facilitated by our products could harm our business and prospects. 46 52 • Any failure to comply with healthcare regulations, including implementation of any change in compliance with healthcare regulations and laws could cause us to incur significant compliance expenses and any failure to comply could subject us to substantial penalties and fines.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
As evidenced by the passage of the American Rescue Plan Act of 2021 and Inflation Reduction Act of 2022, discussed in greater detail below, and the President's Executive Orders in 2025, we expect these challenges to continue and to potentially intensify during 2025, 2026, as political pressures mount, and healthcare payors, including government-controlled health authorities, insurance companies, and managed care organizations, step up initiatives to reduce the overall cost of healthcare, restrict access to higher-priced new medicines, increase the use of generic products and impose overall price cuts.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
Although historically we have been granted FDA orphan drug designation under the Orphan Drug Designation Act for SPN-817 for the treatment of Dravet Syndrome certain drug products and Lennox-Gaustaut Syndrome and for ONAPGO for the treatment of motor fluctuations in adults with advanced PD, product candidates, and we intend to expand our designation for alternative uses where applicable, we may not receive the benefits associated with Orphan Drug Designation.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
Any limitation may result in the expiration of a portion of the net operating loss or tax credit carryforwards before utilization, which would reduce our gross deferred income tax assets. assets, or may result in limitations in the amount of deductions that could be applied to taxable income, which would increase our current tax provision.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
If we materially breach these obligations, The termination of if third parties fail to adequately perform their respective obligations, these arrangements could be terminated which those agreements could result in our inability to develop, manufacture, market and sell products that are covered by such intellectual properties.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
If generics or other versions of our products products, including but not limited to generics containing one or more of the active pharmaceutical ingredients present in our products are approved and successfully commercialized, or if products are developed, approved and successfully commercialized which provide similar benefits of treatment for patients, our business could be materially harmed.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
In the future, the potential inability to obtain sufficient product liability insurance at an acceptable cost, or at all, to protect against potential product liability claims could prevent or inhibit the development and commercialization of the pharmaceutical products we develop.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
Our ability to utilize our U.S. federal and state net operating losses is and other tax attributes are currently limited and may be limited further, under Sections 382 various sections of the Internal Revenue Code. Code of 1986, as amended (Code) such as Section 382 and Section 383.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
If and to the requirement extent the immediate expensing for domestic research and experimental expenditures is not deferred, repealed or any of the capitalization and amortization requirements reenacted or otherwise modified, it may increase our cash taxes and effective tax rate.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
Certain provisions of the HealthCare Reform Law have not been fully interpreted by the regulatory authorities or the courts and certain provisions are subject to a variety of interpretations, which may complicate the Company's compliance with the HealthCare Laws.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedRisk Factors
If we materially breach these obligations, of if third parties fail to adequately perform their respective obligations, these arrangements could be terminated which could result in our inability to develop, manufacture, market and sell products that are covered by such intellectual properties. terminated.
Read it in 10-K Mar 2, 2026 at sec.gov
Quiet changesRisk Factors
Third parties have, and in the future may, receive approval to manufacture and market their own products, including but not limited to generics containing apomorphine hydrochloride, for the treatment of Parkinson’s Disease in the U.S.
Read it in 10-K Mar 2, 2026 at sec.gov
Quiet changesRisk Factors
In addition to competition for our current commercial products, we anticipate that we will face intense competition when if our pipeline product candidates are approved by regulatory authorities and begin their commercialization process.
Read it in 10-K Mar 2, 2026 at sec.gov
Quiet changesRisk Factors
Notwithstanding, However, physicians may nevertheless prescribe products to their patients in a manner that is inconsistent with the approved label, which is known as "off label use".
Read it in 10-K Mar 2, 2026 at sec.gov
Quiet changesRisk Factors
Any penalties, damages, fines, curtailment or restructuring of the Company's operations could adversely affect its ability to operate its business and could impair its financial results.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
On July 31, 2025, the Company completed its previously announced acquisition of Sage when Saphire, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Purchaser), was merged with and into Sage (the Merger), with Sage continuing as the surviving corporation in the Merger as a wholly owned subsidiary of the Company (the Sage Acquisition). At the time of the Sage Acquisition, Sage had an established commercial product in its portfolio, ZURZUVAE.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
•ZURZUVAE® (zuranolone) capsules are the first and only FDA approved oral medicine indicated for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. ZURZUVAE became commercially available in the U.S. in December 2023 as a treatment option for women with PPD. We and our collaboration partner, Biogen, are jointly commercializing ZURZUVAE in the U.S. under a collaboration agreement (Biogen Collaboration Agreement). The Company and Biogen equally share in all operating profits and losses arising from sales of ZURZUVAE in the U.S., with Biogen recording such product sales.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
SPN-820 is a novel, first in class, intracellular enhancer of mechanistic target of rapamycin complex 1 (mTORC1) signaling. Depression is associated with synapse loss and reduced synaptic plasticity in key brain regions including the prefrontal cortex and increasing mTORC1-mediated synaptic plasticity is a potential avenue to treat depression and associated symptoms. SPN-820 selectively binds to intracellular sestrin proteins and subsequently engages a cascade of multi-protein complexes, enhancing mTORC1 signaling. The intracellular mechanism and the lack of binding to cell surface receptors suggests the potential for a differentiated safety profile and is unlikely to have abuse potential.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
The Company initiated a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with MDD. The study will examine the safety and tolerability of SPN-820 2400 mg given intermittently (twice weekly) as an adjunctive treatment to the current baseline antidepressant therapy, as well as assess the rapid onset of improvement in depressive symptoms.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
The Company has granted Biogen sole rights to develop and commercialize zuranolone outside the U.S., other than in Japan, Taiwan and South Korea where it has granted those rights to Shionogi & Co., Ltd. (Shionogi). Shionogi is currently developing zuranolone for the treatment of patients with MDD in Japan, and in the third quarter of 2024, Shionogi reported that it submitted a new drug application (NDA) in Japan for zuranolone for the treatment of MDD. In the third quarter of 2025, Biogen received approval for zuranolone for the treatment of PPD by the European Medicines Agency (EMA) and Medicines Healthcare Regulatory Agency (MHRA) in Europe and the United Kingdom (U.K.) respectively. In the fourth quarter of 2025, zuranolone received Health Canada Authorization in Canada for treatment indicated for adults with PPD. Also in the fourth quarter of 2025, Shionogi received approval for a product containing zuranolone for the treatment of MDD by the Pharmaceuticals and Medical Devices Agency in Japan. No product containing zuranolone is approved for the treatment of MDD in the United States.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
•The Company initiated a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with MDD. The study will examine the safety and tolerability of SPN-820 2400 mg given intermittently (twice weekly) as an adjunctive treatment to the current baseline antidepressant therapy, as well as assess the rapid onset of improvement in depressive symptoms.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
The acquisition method of accounting requires that we recognize the assets acquired and liabilities assumed at their acquisition date fair values. Goodwill is measured as the excess of consideration transferred over the acquisition date net fair values of the assets acquired and the liabilities assumed. The purchase price allocation is a critical accounting policy because the estimation of fair values of acquired assets and assumed liabilities is judgmental and requires various assumptions. Further, the amounts and useful lives assigned to depreciable and amortizable assets versus amounts assigned to goodwill, which is not amortized, can significantly affect the results of operations in the period of and for periods subsequent to a business combination.
Read it in 10-K Mar 2, 2026 at sec.gov
AddedMD&A
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction, and therefore represents an exit price. When identifiable intangible assets, are acquired, we determine the fair values of the assets as of the acquisition date. An income approach, which generally relies upon projected cash flow models, is used in estimating the fair value of the acquired intangible assets. These cash flow projections are based on management's estimates of economic and market conditions including: the estimated future cash flows from revenues of acquired assets; the timing and projection of costs and expenses, discount rates; and tax rates.
Read it in 10-K Mar 2, 2026 at sec.gov
RemovedMD&A
SPN-820 is a first-in-class, orally active small molecule that increases the brain mechanistic target of rapamycin complex 1 (mTORC1) mediated synaptic function intracellularly. SPN-820 does not bind to or modulate any cell surface receptors and therefore is unlikely to have abuse potential given lack of binding to targets implicated in drug abuse. In addition, unlike leucine, it is not incorporated into proteins during protein synthesis, and therefore, it is more available at the target site in the brain than leucine.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
•The FDA has approved an update for the label for Qelbree to include new pharmacodynamic data. The updated label highlights Qelbree’s partial agonist activity at the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter, reinforcing its multimodal pharmacodynamic profile. Additionally, the updated label now includes new
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
•The Company recently presented interim results from an open-label Phase IV trial with Qelbree in 161 adults with ADHD and mood symptoms at the 30th Annual National Psychopharmacology Update™ conference. The improvements in clinician and patient-rated measures of ADHD, depression and anxiety symptoms in the interim data analysis, analyzed for the first 95 patients who completed the trial, are encouraging and suggest that Qelbree's effects may extend to adults with complex ADHD. Efficacy and safety outcomes were consistent with the double-blind, pivotal trial of Qelbree in adult ADHD. Topline results from the full Phase IV trial (all 161 adults) are consistent with the interim results and will be presented at the American Psychiatric Association Annual Meeting in May 2025.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
•The Company received a two-plus year patent term extension from the US Patent and Trademark Office for US Patent number 9,662,338 that covers Qelbree. This extends the original expiration date of the patent to the year 2035.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
•In November 2024, the Company reported topline results from an open label Phase 2a study in patients with treatment-resistant seizures. The study suggested a differentiated profile, with strong efficacy in focal seizures at the 3mg to 4mg twice daily doses. SPN-817 was safe and had acceptable tolerability with two subjects discontinuing because of treatment related adverse events out of the 26 subjects who entered the maintenance period.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
•The Company completed a Phase 1 pharmacokinetic study of two oral formulations in healthy adults. Both formulations of SPN-443 showed adequate bioavailability and were well tolerated.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
accruals and record adjustments when rebate trends, rebate programs and contract terms, legislative changes, or other significant events indicate that a change in reserve is appropriate. Historically, adjustments to rebate accruals have not been material to net earnings.
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedMD&A
Year Ended December 31, Change 2025 2024 2023 Amount Percent Net product sales Qelbree $ 304,654 $ 241,273 $ 140,192 $ 101,081 72% 63,381 26% GOCOVRI 146,824 130,824 119,637 11,187 9% 16,000 12% Oxtellar XR 40,700 99,464 113,404 (13,940) (12)% (58,764) (59)% APOKYN 47,771 73,926 75,083 (1,157) (2)% (26,155) (35)% Trokendi XR 42,421 63,201 94,336 (31,135) (20,780) (33)% ONAPGO 17,254 — 17,254 100% Other(1) 26,912 29,008 31,281 (2,273) (2,096) (7)% Total net product sales $ 626,536 $ 637,696 $ 573,933 $ 63,763 11% (11,160) (2)% Collaboration revenue (ZURZUVAE) 52,996 — 52,996 100% Royalty, licensing licensing, and other revenues 39,420 24,121 33,588 (9,467) (28)% 15,299 63% Total revenues $ 718,952 $ 661,817 $ 607,521 $ 54,296 57,135 9%
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The following table provides the components of other income (expense) during the years indicated (dollars in thousands):Year Ended December 31, Change 2025 2024 2023 Amount Percent Interest income & and other income, net $13,253 $16,204 $ 16,204 (2,951) (18)% Total $13,253 $16,204 $ 10,453 $ 5,751 55% Interest expense — (1,321) 1,321 (100)% Noncash interest expense on nonrecourse liability related to sale of future royalties — (562) 562 (100)% Noncash interest expense on debt — (532) 532 (100)% Total $ 16,204 $ 8,038 $ 8,166 102% (2,951) (18)%
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
While we expect continued profitability in future years, we anticipate there may be significant variability from year to year in the level of our profits particularly due to continued market and payor pressures for our commercial products; the unfavorable impact of the loss of patent exclusivity for Trokendi XR in January 2023 and Oxtellar XR in September 2024; the potential unfavorable impact of the forthcoming loss of exclusivity of XADAGO; funding for research and development of our product candidates; and the additional funding to for the launch ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, of ONAPGO, which was approved by the FDA in February 2025 and launched in April 2025, and the additional funding for the marketing of ZURZUVAE which was acquired as part of the Sage Acquisition in July 2025.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The increase decrease in cash flows provided by operating activities was primarily due to higher the decrease in net income earnings for the year ended December 31, 2024 compared to the same period in prior year, and 2025 as well as changes in working capital which reflects the timing impacts of cash collections on receivables and settlement of payables. capital.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
If the carrying amount of the asset exceeds its fair value, the Company writes down the asset to its estimated fair value, and an impairment loss equal to the difference between the assets fair value and carrying value is recognized in the consolidated statement of earnings (loss) in the period at which such determination is made.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
Cash and cash equivalents, marketable securities, and marketable securities restricted cash are as follows comprised of the following (dollars in thousands):December 31, 2024 2025 December 31, 2023 2024 Cash and cash equivalents $ 128,448 $ 69,331 $ 75,054 Marketable securities 180,222 384,281 179,820 Long-term marketable securities Restricted cash 1,450 — 16,617 Total $ 310,120 $ 453,612 $ 271,491
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The table below provides information regarding our selling, Selling, general, and administrative (SG&A) expenses for the years indicated (dollars in thousands):Year Ended December 31, Change 2025 2024 2023 Amount Percent Selling and marketing expense $ 227,293 $229,186 288,651 $227,293 $ (1,893) (1)% 61,358 27% General and administrative expense 196,912 94,289 107,175 (12,886) (12)% 102,623 109% Total $ 321,582 $336,361 485,563 $321,582 $ (14,779) (4)% 163,981 51%
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The provision for sales discounts increased from $65.9 million in 2023 to $69.5 million in 2024 to $73.0 million in 2025 primarily attributable to new product launched in 2025 and higher net product Qelbree sales in 2024 2025 compared to 2023. 2024.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
This decrease was primarily due to $11.9 a decrease of $20.7 million of adjustments in the estimated provision for product returns related to prior year sales offset by higher net product sales and timing of related return activity. sales.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The Company is actively monitoring returns activity in light of the timeline loss of exclusivity and actual and possible further future sales decline based on timing of generic entry.
Read it in 10-K Mar 2, 2026 at sec.gov
RewordedMD&A
The following table provides information regarding the contingent Contingent consideration gain loss (gain) during the periods indicated (dollars in thousands):Year Ended December 31, Change 2025 2024 2023 Amount Percent Contingent consideration gain loss (gain) $ 25,419 $ (6,110) $ (1,517) $ (4,593) 303% 31,529 (516)%
Read it in 10-K Mar 2, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SUPN/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.